BackSilexion Therapeutics - Warrants(14/08/2029) Overview
Silexion Therapeutics Corp - Warrants(14/08/2029)

Silexion Therapeutics - Warrants(14/08/2029) Return on Equity

Latest ROE for Silexion Therapeutics - Warrants(14/08/2029): -316.15% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-316.15%

Return on Equity

-316.15%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Silexion Therapeutics - Warrants(14/08/2029) (SLXNW) FAQ

Silexion Therapeutics - Warrants(14/08/2029) (SLXNW) currently reports a ROE of -316.15%. That is below the sector sector average of -4.47%. Use the charts on this page to explore Silexion Therapeutics - Warrants(14/08/2029)'s ROE history and peer comparisons.

Silexion Therapeutics - Warrants(14/08/2029)'s ROE of -316.15% is lower than the its sector sector average of -4.47%. That is roughly 6975.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Silexion Therapeutics - Warrants(14/08/2029)'s current -316.15% should be judged against industry norms (sector average: -4.47%) and against SLXNW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -316.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.47%. From there, open related valuation or income-statement pages for Silexion Therapeutics - Warrants(14/08/2029), and consider following SLXNW for alerts when major investors trade the stock.